The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.

Provided is a drug carrier for treatment of atherosclerosis including a biocompatible amphipathic polymer including a macrophage lignad polymer and a hydrophobic substance, and a hydrophobic drug.

The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability. The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours.

An aqueous dispersion of particles comprising a resin having at least one repeating unit of formula I, II and/or III and which is obtainable by contacting in a liquid comprising water, a compound A comprising at least 2 functional groups selected from the group of functional groups —X—C(═O)—CHR1-C(═O)—R2, —X—C(═O)—C≡C—R2; or —X—C(═O)—CR1=CR2-NR11R12, the functional groups are linked by a linking group comprising a polyester, polyether, polyolefin, polydimethylsiloxane or polycarbonate chain with a compound B comprising at least two —NH.sub.2, —NH.sub.3.sup.+ or —N═C═O, wherein X, R1, R2, R3, R11 and R12 have the same meaning as that defined in the claims and w. The invention also includes a method of producing the aqueous dispersion.

##STR00001##

A telodendrimer-nanolipoprotein particle (t-NLP), comprising one or more membrane forming lipids, one or more telodendrimers, and a scaffold protein and a Chlamydia major outer membrane protein (MOMP) comprising a MOMP hydrophobic region, and related compositions methods and systems.

A silica that is superior in terms of fluidity, oil absorption ability, and compression moldability to conventional silica used as a pharmaceutical additive, and is suitable as an additive for formulations such as pharmaceuticals. A porous silica particle composition having the following properties: (1) a BET specific surface area from 250 to 1,000 m.sup.2/g; (2) an average particle diameter from 1 to 150 μm; (3) a pore volume from 0.1 to 8.0 cm.sup.3/g; and (4) an oil absorption capacity from 2.2 to 5.0 mL/g.